Plasma advanced glycation end products (AGEs), receptors for AGEs and their correlation with inflammatory markers in middle school-age children.
OBJECTIVE
Advanced glycation end products (AGEs) and/or their receptors (RAGE) are significantly positively correlated with adiposity, inflammation, dyslipidemia, and insulin resistance in adults. However, the relationships between AGEs, RAGE, and adiposity-related comorbidites in children have not been well studied.


METHODS
In a cross-sectional study of 88 children (age 11-15 years) from the New York area enrolled in the Reduce Obesity and Diabetes (ROAD) study, we examined the correlation of the AGE N(ε)-(carboxymethyl)lysine (CML), soluble RAGE (sRAGE), and endogenous secretory RAGE (esRAGE) with adiposity, inflammatory markers [interleukin-6 (IL-6), C-reactive protein, tumor necrosis factor-α], adiponectin, lipids, insulin sensitivity, and insulin secretory capacity.


RESULTS
Pediatric CML levels were ~20% below average adult levels. CML was significantly (p < 0.05) positively correlated with age and insulin sensitivity and negatively with adiposity, dyslipidemia and IL-6. sRAGE correlated positively with esRAGE and negatively with adiposity and IL-6. Both sRAGE and esRAGE correlated negatively with insulin secretory capacity.


CONCLUSIONS
Our findings suggest that unlike adults, CML is negatively associated with adiposity and adiposity-related comorbidity risk in children. As in adults, sRAGE and esRAGE were, to varying degrees, negatively correlated with body fatness and risk factors for adiposity-related comorbidities.
Pediatrics, Winthrop University Hospital, Mineola, N.Y., USA.
S
S
Accacha
W
W
Rosenfeld
A
A
Jacobson
L
L
Michel
F J
FJ
Schnurr
S
S
Shelov
S
S
Ten
C
C
Boucher-Berry
D E
DE
Carey
P W
PW
Speiser
B
B
Lowell
R
R
Conroy
M
M
Klein
I
I
Fennoy
R
R
Rapaport
M
M
Rosenbaum
D052242:Adiponectin / Q000097:blood; D050154:Adiposity; D000293:Adolescent; D000328:Adult; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D002648:Child; D003430:Cross-Sectional Studies; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood*; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D000067759:Receptor for Advanced Glycation End Products / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
C499918:ADIPOQ protein, human; D052242:Adiponectin; D015415:Biomarkers; D017127:Glycation End Products, Advanced; C508600:IL6 protein, human; D018836:Inflammation Mediators; D015850:Interleukin-6; D000067759:Receptor for Advanced Glycation End Products; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein